PrintFriendly
Industry News
|
Friday, January 18, 2019  The acquisition was approved on December 5th, 2018. |
|
Monday, December 17, 2018  Sangamo announced it has treated the first patient in a Phase 1/2 clinical trial evaluating SB-FIX, the company’s investigational gene therapy for patients with hemophilia B. |
|
Monday, November 19, 2018  UniQure recently announced initial clinical data from patients treated in an open-label phase IIb dose-confirmation study of AMT-061, the company’s investigational gene therapy treatment for patients with severe and moderately severe hemophilia B. |
|
Thursday, August 30, 2018  Bayer received FDA approval for new extended half-life hemophilia A product for patients 12 yrs and older. |
|
Thursday, August 23, 2018  The new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose. |
|
Thursday, August 23, 2018 The therapy is for people with severe and moderately severe hemophilia B. |
|
Friday, August 17, 2018  The therapy in trial is for the prophylactic treatment of individuals with hemophilia A or B with inhibitors. |
|
Thursday, August 9, 2018  The company reported on preliminary data from the Phase 1/2 clinical trial designed to evaluate SB-525, the company’s gene therapy program for people with hemophilia A. |
|
Wednesday, August 8, 2018  The therapy is administered via a one-time intravenous infusion, which is designed to elicit the production of therapeutic levels of factor VIII. |
|
Wednesday, August 8, 2018  The preliminary injunction was part of an ongoing patent lawsuit. |